Dianthus (DNTH) Q2 Loss Widens 80%
Dianthus Therapeutics (NASDAQ:DNTH), a clinical-stage biotech developing therapies for autoimmune neuromuscular diseases, reported second quarter results on August 7, 2025. Net loss per share (GAAP) was $(0.88). GAAP revenue was $0.2 million for Q2 2025. With significant increases in both research and administrative costs, the company ended the period well-capitalized but still years from potential commercialization. This quarter highlighted clinical progress alongside rising expenses and a continued focus on upcoming study milestones, providing important context for investors following the company’s path through late-stage trials.
Source: Analyst estimates for the quarter provided by FactSet.
Dianthus Therapeutics is advancing therapies for severe autoimmune and neuromuscular diseases. Its main focus is claseprubart, a monoclonal antibody treatment targeting the classical complement pathway for conditions like generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN).
Source Fool.com
